Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec 10;81(24):2136-40.
doi: 10.1212/01.wnl.0000437305.37850.f9. Epub 2013 Nov 22.

Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology

Affiliations
Review

Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology

Robert G Miller et al. Neurology. .

Abstract

Amyotrophic lateral sclerosis (ALS) is a lethal, progressive neurodegenerative disease characterized by loss of motor neurons.(1) Patients with ALS lose function in the limbs, speech, swallowing, and breathing muscles. The cause of the disease is still not known for most patients. Approximately 25,000 people in the United States have ALS, and 5,000 people are diagnosed with ALS annually in the United States.(1) Most patients die from respiratory failure 2 to 5 years after onset of symptoms. Cognitive dysfunction is seen in 20% to 50% of patients.(2) The disease burden for patients and caregivers is enormous. The average cost of care has been estimated at $50,000 per patient per year.(3.)

PubMed Disclaimer

References

    1. National Institute of Neurological Disorders and Stroke. Amyotrophic lateral sclerosis fact sheet. Available at: http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_AL.... Accessed February 6, 2012.
    1. Woolley SC. Utility of the ALS cognitive behavioral Screen. Neurodegen Dis Manage 2011;1:473–479
    1. Schepelmann K, Winter Y, Spottke A, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol 2010;257:14–23 - PubMed
    1. Miller RG, Rosenberg JA, Gelinas DF, et al. ; ALS Practice Parameters Task Force Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1999;52:1311–1323 - PubMed
    1. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1218–1226 - PMC - PubMed

Publication types

MeSH terms